Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
NEW ORLEANS, Jan. 25, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 22, 2016 to file lead plaintiff applications in a securities class action lawsuit against HeartWare International Inc. (Nasdaq:HTWR), if they purchased the Company’s securities between June 10, 2014 and January 11, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
What You May Do
If you purchased shares of HeartWare and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 22, 2016.
About the Lawsuit
HeartWare and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On September 9, 2015, HeartWare disclosed that it was halting enrollment in the trial for MVAD, a pump that it was developing, because of a manufacturing problem. Thereafter, on October 12, 2015, HeartWare disclosed that patients had suffered adverse events and the trial would be further delayed. Finally, on January 11, 2016, HeartWare revealed that approximately half of the patients implanted with the MVAD experienced serious adverse events and the trial would be delayed indefinitely. Following these announcements, the price of HeartWare's stock plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
